Sun G, Wang Z, Han Q, Liu B, Chen H. Complete remission in a pretreated, microsatellite-stable, KRAS-mutated colon cancer patient after treatment with sintilimab and bevacizumab and platinum-based chemotherapy: a case...
KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance . Virchows Arch 2013; 462 :39–46.Dijkstra JR, Heideman DA, Meijer GA, Boers JE, t Hart NA, Diebold J, et al. KRAS mutation analysis on low percentage of colon cancer cells: the ...
patients, the expression of PD-L1 in tumours in the TP53/KRAS comutation group was increased, and the proportion of CD8 + T cells in TME was higher, which was consistent with the clinical benefit of TP53, KRAS or TP53/KRAS-mutated cancer patients after treatment with PD-1 inhibitors113. ...
co-mutation ofKEAP1/STK11was more common in patients withKRASG13-mutated lung cancer than in patients withKRASG12D-mutated lung cancer, and co-mutation ofKEAP1/STK11withKRASG13was associated with poor prognosis and treatment resistance28. ...
Treatment of human lung cancer cells with KRA-533 resulted in increased KRAS activity and suppression of cell growth. Lung cancer cell lines with KRAS mutation were relatively more sensitive to KRA-533 than cell lines without KRAS mutation. Mutating one of the hydrogen-bonds among the KRA-533 ...
This mutation confers a poor prognosis in the metastatic setting, and a high risk of cancer recurrence as seen in several studies [6–9]. It is mutated in one-third of all cancers including colon cancer and pancreatic cancer. In addition, the three human RAS genes (NRAS, HRAS, KRAS) ...
Irinotecan Fluorouracil Plus Leucovorin Is Not Superior to Fluorouracil Plus Leucovorin Alone As Adjuvant Treatment for Stage III Colon Cancer: Results of ... PURPOSE: Randomized studies have shown that irinotecan (CPT-11) extends survival in metastatic colorectal cancer patients when administered in sec...
In particular, approximately 30%–40% of colon cancers harbor aKRASmutation.KRASmutations in colon cancers have been associated with poorer survival and increased tumor aggressiveness. Additionally,KRASmutations in colorectal cancer lead to resistance to select treatment strategies. In this review we ...
We performed deep sequencing of 27 KRAS G12-positive lung tumors to determine the prevalence of other oncogenic mutations within KRAS or within commonly mutated downstream genes that could confer resistance at the time of treatment. We also passaged patient-derived xenografts to assess the potential...
3. Zhu G, et al. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer. 2021 Nov 6;20(1):143. 4. Fakih M, et al. Real-World Study of Characteristics and Treatm...